PRODUCT INFORMATION



Mubritinib

Item No. 12096

CAS Registry No.:	366017-09-6	
Formal Name:	1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)	
	phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]	
	butyl]-1H-1,2,3-triazole	
Synonym:	TAK-165	
MF:	C ₂₅ H ₂₃ F ₃ N ₄ O ₂	
FW:	468.5	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 222, 306 nm	
Supplied as:	A crystalline solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

Mubritinib is supplied as a crystalline solid. A stock solution may be made by dissolving the mubritinib in the solvent of choice. Mubritinib is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of mubritinib in these solvents is approximately 5 mg/ml.

Mubritinib is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

Mubritinib is a selective inhibitor of the human epidermal growth factor receptor 2 (HER2), inhibiting HER2 phosphorylation with an IC₅₀ value of 6 nM.1 It is without effect on EGFR, FGFR, PDGFR, JAK1, Src, and Blk (IC₅₀ > 25 μ M).¹ Mubritinib inhibits the proliferation of breast, bladder, kidney, and prostate cancer cells in vitro and in vivo.1,2

References

- 1. Nagasawa, J., Mizokami, A., Koshida, K., et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int. J. Urol. 13, 587-592 (2006).
- 2. Sridhar, S.S., Seymour, L., and Shepherd, F.A. Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4(7), 397-406 (2003).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

SAFETY DATA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM